Compare VRA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | CGTX |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6M | 158.8M |
| IPO Year | 2010 | 2021 |
| Metric | VRA | CGTX |
|---|---|---|
| Price | $2.21 | $1.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $4.00 | $2.88 |
| AVG Volume (30 Days) | ★ 1.8M | 977.9K |
| Earning Date | 12-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $332,526,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $0.22 |
| 52 Week High | $5.79 | $3.83 |
| Indicator | VRA | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 54.36 |
| Support Level | $2.52 | $1.58 |
| Resistance Level | $2.99 | $1.81 |
| Average True Range (ATR) | 0.32 | 0.13 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 1.63 | 82.30 |
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.